ALKS logo

ALKERMES PLC

ALKSNASDAQ
🏆 #1097 by market capEarnings Oct 28US Equity
$303.07▼ $22.37 (−7.38%)
Simulated price
🔔
Track ALKS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.4%
7d▲ 600.3%
14d▲ 558.2%
30d▲ 538.8%
ytd▲ 983.6%
1y▲ 944.0%
🏦Market Cap
$6.85B
Small Cap
📈Revenue Growth (YoY)
-5.3%
Declining
📊Gross Margin
84.6%
High
💵FCF Margin
13.3%
Healthy
⚖️P/S Ratio
4.1x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$301.94 – $308.15
52-Week Range
$27.00 – $55.67
Volume
$4.54B
Avg Volume
$3.47B
Shares Outstanding
167.8M
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$1.48B
Last Q Revenue
$496M
P/E Ratio
101.4
P/S Ratio
4.1x
EPS (TTM)
$0.40
Dividend Yield
0.00%
Dilution (1yr)
+1.3%

Why Investors Own ALKS

  • ✓High-growth profile — revenue up -4.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 69% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALKS logo

ALKERMES PLC

ALKS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.5B▼ −5.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
86.7%▲ +2.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$254M▼ −39.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$480M▲ +18.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
168.7M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1.0B▲ +$834M YoY
StockOtter · stockotter.space

About ALKERMES PLC

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$298.22
▼ −1.6% Downside
High Target$325.24
Low Target$222.99
Based on 31 analysts

Latest News & Updates

🚀
Reuters·2h ago

ALKERMES PLC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift ALKS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ALKERMES PLC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.